Company: NCNA
Filing Date: 2025-03-20
Form Type: 20-F
Source: 0000950170-25-042709
Chunk: 58

Company: NuCana plc
Filing Date: 2025-03-20
Form: 20-F
Item: Item 3
Chunk 58
---
 product from alternate sources at acceptable prices in a timely manner could impede, delay, limit or prevent our development efforts.
 We have entered into, and may in the future enter into, collaborations with third parties to discover or develop product candidates. If these collaborations are not successful, our business could be adversely affected.
 We have, and may potentially in the future, enter into collaborations with third parties. On December 31, 2021, our research, collaboration and license agreement with Cardiff University and University College Cardiff Consultants Ltd., or Cardiff Consultants, for the design, synthesis, characterization and evaluation of ProTides, as amended, or the Cardiff Agreement, expired pursuant to its terms. In connection with the expiration, we exercised our right under the Cardiff Agreement to extend the license of the ProTide-related intellectual property owned or controlled by Cardiff University as of the date of the Cardiff Agreement or owned or controlled by Cardiff University during the term of that Agreement, which we refer to as the Cardiff intellectual property, granted to NuCana under the Cardiff Agreement for a period of three months from the expiration of the Cardiff Agreement in order to continue evaluating additional ProTides generated under the Cardiff Agreement. This period expired on March 31, 2022. See “Collaboration and License Agreements–Cardiff University License” in this Annual Report for more information on the terms of our agreement and its expiration. While we chose not to further renew the Cardiff Agreement, the expiration of the Cardiff Agreement may result in a reduction in our ability to identify and develop additional ProTides.
 In any collaboration that we may enter into, we would expect to have limited control over the amount and timing of resources that our collaborators dedicate to the collaboration efforts, including, if applicable, the development of ProTides. Our ability to generate potential additional ProTides from any such arrangements will depend on our and our collaborators’ abilities to successfully perform the functions assigned to each of us in these arrangements. In addition, our collaborators have the ability to abandon research or development projects and terminate applicable agreements. Our prior collaboration and any collaborations we enter into in the future, may pose several risks, including the following:
 •collaborators have significant discretion in determining the efforts and resources that they will apply to these collaborations;
 •collaborators may not perform their obligations as expected;
 •the clinical trials conducted as part of, or as a result of, these collaborations may not be successful;
 •collaborators may not pursue development or commercialization of any product candidates that achieve regulatory approval or